# FDA Approves T-DXd for HER2-Positive Early Breast Cancer Neoadjuvant and Adjuvant Treatment

> fda · REPORTED · 2026-05-18

The FDA approved trastuzumab deruxtecan (T-DXd) for the neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on improved pathological complete response and invasive disease-free survival rates in clinical trials. This expands the use of T-DXd earlier in the breast cancer treatment journey, adding a potentially curative-intent option for patients who previously had limited antibody-drug conjugate access outside the metastatic setting.

About AstraZeneca / T-DXd / FDA: Trastuzumab deruxtecan (T-DXd, Enhertu) is an HER2-directed antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo for the treatment of HER2-positive and HER2-low breast cancer across multiple disease stages.

- Company: AstraZeneca / T-DXd / FDA
- Sector: oncology
- Primary source: https://www.oncnursingnews.com/clinical/breast-cancer

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.